Health
Opaganib shows promise in preventing ARDS-induced thrombosis – Drug Target Review
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Posted: 16 December 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Opaganib (Yeliva®), a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) reduced thrombosis in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
According to the researchers, their findings suggest opaganib may be of benefit to patients…
-
Noosa News17 hours agoPill checking to resume in Queensland months after government axed funding
-
Business20 hours agoWhy Austal, Boss Energy, Harvey Norman, and NextDC shares are charging higher today
-
Noosa News15 hours agoMother who faked daughter’s medical conditions, forged documents, granted immediate parole
-
Business21 hours agoASX shares are expensive. Here’s why you should be buying anyway